Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 64

1.

Direct whole-genome deep-sequencing of human respiratory syncytial virus A and B from Vietnamese children identifies distinct patterns of inter- and intra-host evolution.

Do LA, Wilm A, Van Doorn HR, Lam HM, Sim S, Sukumaran R, Tran AT, Nguyen BH, Tran TT, Tran QH, Vo QB, Dac NA, Trinh HN, Nguyen TT, Binh BT, Le K, Nguyen MT, Thai QT, Vo TV, Ngo NQ, Dang TK, Cao NH, Tran TV, Ho LV, Farrar J, Jong Md, Chen S, Nagarajan N, Bryant JE, Hibberd ML.

J Gen Virol. 2015 Dec;96(12):3470-83.

PMID:
26407694
2.

Respiratory syncytial virus fusion protein promotes TLR-4-dependent neutrophil extracellular trap formation by human neutrophils.

Funchal GA, Jaeger N, Czepielewski RS, Machado MS, Muraro SP, Stein RT, Bonorino CB, Porto BN.

PLoS One. 2015 Apr 9;10(4):e0124082. doi: 10.1371/journal.pone.0124082. eCollection 2015.

3.

Safety and Effectiveness of Palivizumab in Children at High Risk of Serious Disease Due to Respiratory Syncytial Virus Infection: A Systematic Review.

Wegzyn C, Toh LK, Notario G, Biguenet S, Unnebrink K, Park C, Makari D, Norton M.

Infect Dis Ther. 2014 Dec;3(2):133-58. doi: 10.1007/s40121-014-0046-6. Epub 2014 Oct 9. Review.

4.

Prophylaxis with a respiratory syncytial virus (RSV) anti-G protein monoclonal antibody shifts the adaptive immune response to RSV rA2-line19F infection from Th2 to Th1 in BALB/c mice.

Boyoglu-Barnum S, Chirkova T, Todd SO, Barnum TR, Gaston KA, Jorquera P, Haynes LM, Tripp RA, Moore ML, Anderson LJ.

J Virol. 2014 Sep;88(18):10569-83. doi: 10.1128/JVI.01503-14. Epub 2014 Jul 2.

5.

Development of safe and effective RSV vaccine by modified CD4 epitope in G protein core fragment (Gcf).

Cheon IS, Shim BS, Park SM, Choi Y, Jang JE, Jung DI, Kim JO, Chang J, Yun CH, Song MK.

PLoS One. 2014 Apr 15;9(4):e94269. doi: 10.1371/journal.pone.0094269. eCollection 2014.

6.

Epidemiological changes of respiratory syncytial virus (RSV) infections in Israel.

Hirsh S, Hindiyeh M, Kolet L, Regev L, Sherbany H, Yaary K, Mendelson E, Mandelboim M.

PLoS One. 2014 Mar 3;9(3):e90515. doi: 10.1371/journal.pone.0090515. eCollection 2014.

7.

Influence of respiratory syncytial virus strain differences on pathogenesis and immunity.

Melero JA, Moore ML.

Curr Top Microbiol Immunol. 2013;372:59-82. doi: 10.1007/978-3-642-38919-1_3.

8.

Nanoparticle vaccines encompassing the respiratory syncytial virus (RSV) G protein CX3C chemokine motif induce robust immunity protecting from challenge and disease.

Jorquera PA, Choi Y, Oakley KE, Powell TJ, Boyd JG, Palath N, Haynes LM, Anderson LJ, Tripp RA.

PLoS One. 2013 Sep 10;8(9):e74905. doi: 10.1371/journal.pone.0074905. eCollection 2013.

9.

Molecular epidemiology and phylodynamics of the human respiratory syncytial virus fusion protein in northern Taiwan.

Chi H, Liu HF, Weng LC, Wang NY, Chiu NC, Lai MJ, Lin YC, Chiu YY, Hsieh WS, Huang LM.

PLoS One. 2013 May 29;8(5):e64012. doi: 10.1371/journal.pone.0064012. Print 2013.

10.

Combination therapy using monoclonal antibodies against respiratory syncytial virus (RSV) G glycoprotein protects from RSV disease in BALB/c mice.

Caidi H, Harcourt JL, Tripp RA, Anderson LJ, Haynes LM.

PLoS One. 2012;7(12):e51485. doi: 10.1371/journal.pone.0051485. Epub 2012 Dec 27.

11.

Generation by reverse genetics of an effective, stable, live-attenuated newcastle disease virus vaccine based on a currently circulating, highly virulent Indonesian strain.

Xiao S, Nayak B, Samuel A, Paldurai A, Kanabagattebasavarajappa M, Prajitno TY, Bharoto EE, Collins PL, Samal SK.

PLoS One. 2012;7(12):e52751. doi: 10.1371/journal.pone.0052751. Epub 2012 Dec 21.

12.

Respiratory syncytial virus fusion protein-induced toll-like receptor 4 (TLR4) signaling is inhibited by the TLR4 antagonists Rhodobacter sphaeroides lipopolysaccharide and eritoran (E5564) and requires direct interaction with MD-2.

Rallabhandi P, Phillips RL, Boukhvalova MS, Pletneva LM, Shirey KA, Gioannini TL, Weiss JP, Chow JC, Hawkins LD, Vogel SN, Blanco JC.

MBio. 2012 Aug 7;3(4). pii: e00218-12. doi: 10.1128/mBio.00218-12. Print 2012.

13.

Antibodies to the central conserved region of respiratory syncytial virus (RSV) G protein block RSV G protein CX3C-CX3CR1 binding and cross-neutralize RSV A and B strains.

Choi Y, Mason CS, Jones LP, Crabtree J, Jorquera PA, Tripp RA.

Viral Immunol. 2012 Jun;25(3):193-203. doi: 10.1089/vim.2011.0094. Epub 2012 May 2.

14.

Dual role of respiratory syncytial virus glycoprotein fragment as a mucosal immunogen and chemotactic adjuvant.

Kim S, Joo DH, Lee JB, Shim BS, Cheon IS, Jang JE, Song HH, Kim KH, Song MK, Chang J.

PLoS One. 2012;7(2):e32226. doi: 10.1371/journal.pone.0032226. Epub 2012 Feb 27.

15.

Whole genome sequencing and evolutionary analysis of human respiratory syncytial virus A and B from Milwaukee, WI 1998-2010.

Rebuffo-Scheer C, Bose M, He J, Khaja S, Ulatowski M, Beck ET, Fan J, Kumar S, Nelson MI, Henrickson KJ.

PLoS One. 2011;6(10):e25468. doi: 10.1371/journal.pone.0025468. Epub 2011 Oct 6.

16.

Progress in understanding and controlling respiratory syncytial virus: still crazy after all these years.

Collins PL, Melero JA.

Virus Res. 2011 Dec;162(1-2):80-99. doi: 10.1016/j.virusres.2011.09.020. Epub 2011 Sep 22. Review.

17.

Molecular epidemiology and evolution of human respiratory syncytial virus and human metapneumovirus.

Gaunt ER, Jansen RR, Poovorawan Y, Templeton KE, Toms GL, Simmonds P.

PLoS One. 2011 Mar 1;6(3):e17427. doi: 10.1371/journal.pone.0017427.

18.

Impact of pollution, climate, and sociodemographic factors on spatiotemporal dynamics of seasonal respiratory viruses.

Sloan C, Moore ML, Hartert T.

Clin Transl Sci. 2011 Feb;4(1):48-54. doi: 10.1111/j.1752-8062.2010.00257.x. Review.

19.

Soluble respiratory syncytial virus fusion protein in the fully cleaved, pretriggered state is triggered by exposure to low-molarity buffer.

Chaiwatpongsakorn S, Epand RF, Collins PL, Epand RM, Peeples ME.

J Virol. 2011 Apr;85(8):3968-77. doi: 10.1128/JVI.01813-10. Epub 2011 Feb 9.

20.

Analysis of respiratory syncytial virus preclinical and clinical variants resistant to neutralization by monoclonal antibodies palivizumab and/or motavizumab.

Zhu Q, McAuliffe JM, Patel NK, Palmer-Hill FJ, Yang CF, Liang B, Su L, Zhu W, Wachter L, Wilson S, MacGill RS, Krishnan S, McCarthy MP, Losonsky GA, Suzich JA.

J Infect Dis. 2011 Mar 1;203(5):674-82. doi: 10.1093/infdis/jiq100. Epub 2011 Jan 5.

Items per page

Supplemental Content

Write to the Help Desk